March 2026
M	T	W	T	F	S	S
	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Ney Carter Borges on Colchicine As 2ry Prevention in Atherosclerotic CVD

Ney Carter Borges/LinkedIn

Jan 28, 2026, 13:55

Ney Carter Borges on Colchicine As 2ry Prevention in Atherosclerotic CVD

Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn:

”Low-dose colchicine (0.5 mg/day) has emerged as an effective anti-inflammatory strategy for secondary prevention in atherosclerotic cardiovascular disease.

By inhibiting microtubule assembly, colchicine suppresses activation of the NLRP3 inflammasome, leading to reduced interleukin-1β and interleukin-6 signaling, key drivers of plaque inflammation and instability.

Clinical trial data demonstrate that colchicine significantly stabilizes atherosclerotic plaques, attenuates neutrophil activation, and reduces thrombogenic potential.

A pooled analysis of randomized trials shows a 25% relative reduction in major adverse cardiovascular events (HR ~0.75), with consistent reductions in myocardial infarction (≈23%), ischemic stroke (≈22%), and cardiovascular mortality (≈34%).

These benefits occur without an increase in non-cardiovascular mortality and with good tolerability in most patients.

Taken together, these findings position colchicine as a third pillar of secondary prevention, complementing lipid-lowering and antithrombotic therapies by targeting residual inflammatory risk in patients with established atherosclerosis.”

Ney Carter Borges on Colchicine As 2ry Prevention in Atherosclerotic CVD